ArticleCancer medicine2025
Outcomes of Infants and Young Children With CNS Embryonal Tumors Using Pre-Irradiation Chemotherapy: A Decade Long Experience.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundManagement of infants and young children with embryonal tumors of the central nervous system remains a challenge. We report the outcomes in these children with the strategy of surgery, pre-irradiation chemotherapy, and delayed radiation. PROCEDURE: Children less than 3 years and diagnosed with medulloblastoma(MB), atypical teratoid rhabdoid tumor(ATRT), embryonal tumor with multilayered rosettes(ETMR), embryonal tumor tumors NOS(ET NOS) and pineoblastoma(PB), underwent standard evaluation and staging. They were treated with maximal safe surgical excision followed by pre-irradiation chemotherapy (cyclophosphamide, etoposide and carboplatin) up to 36 months of age or till disease progression, followed by either craniospinal (standard 35Gy or reduced-dose 23.4 Gy) with boost to a total of 54.8 Gy or focal irradiation depending on attained age, residual tumor, and metastasis.
results72 children between January 2011 and December 2022 were eligible for inclusion; medulloblastoma-43 (59.7%), ATRT-9 (12.9%), ET NOS-8 (11.1%), ETMR-8 (11.1%) and PB-4 (5.6%). The median chemotherapy cycles were 6 (range 2-15); 41 children went on to receive RT. For the entire cohort, 3-year event-free survival (EFS) and overall survival (OS) were 39.8% ± 5.8% and 44.8% ± 5.9%. For medulloblastoma, 3-year PFS and OS were 57.4% ± 7.6% and 62% ± 7.5%. Multivariable analysis for survival in medulloblastoma found group 3 metastatic (HR 3.5, 95% CI 1.16-10.99, p = 0.026) and postoperative residual tumor (HR 1.9%, 95% CI 0.52-5.31, p = 0.24) to be significant prognostic factors. Among long-term survivors (n = 27), over 80% have late toxicities requiring intervention.
conclusionThe use of moderate-intensity pre-irradiation chemotherapy is safe and effective in infants and young children with CNS ETs. Despite inferior outcomes compared to high-dose chemotherapy and intraventricular chemotherapy, this strategy could be used in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.